<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05611957</url>
  </required_header>
  <id_info>
    <org_study_id>18529</org_study_id>
    <secondary_id>J1I-MC-GZBL</secondary_id>
    <nct_id>NCT05611957</nct_id>
  </id_info>
  <brief_title>A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function</brief_title>
  <official_title>A Parallel-group, Phase 1, Open-label Study to Investigate the Pharmacokinetics of LY3437943 in Participants With Renal Impairment Compared With Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to assess the amount of study drug that reaches the&#xD;
      bloodstream and the time it takes for the body to get rid of it when given to participants&#xD;
      with renal (kidney) impairment compared to healthy participants. The study will last up to 5&#xD;
      weeks, excluding screening.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2022</start_date>
  <completion_date type="Anticipated">August 18, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 18, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area under the concentration versus time curve from time zero to infinity (AUC0-∞) of LY3437943</measure>
    <time_frame>Predose up to 31 days postdose</time_frame>
    <description>PK: AUC0-∞ of LY3437943</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Maximum observed concentration (Cmax) of LY3437943</measure>
    <time_frame>Predose up to 31 days postdose</time_frame>
    <description>PK: Cmax of LY3437943</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy</condition>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>LY3437943 (Control)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3437943 administered subcutaneous (SC) to participants with normal renal function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3437943 (Severe Renal Impairment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3437943 administered SC to participants with severe renal impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3437943 (End-Stage Renal Disease)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3437943 administered SC to participants with end-stage renal disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3437943</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>LY3437943 (Control)</arm_group_label>
    <arm_group_label>LY3437943 (End-Stage Renal Disease)</arm_group_label>
    <arm_group_label>LY3437943 (Severe Renal Impairment)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Normal Participants:&#xD;
&#xD;
          -  Healthy male and female participants as determined by physical examination&#xD;
&#xD;
          -  Participants with normal renal function assessed by estimated glomerular filtration&#xD;
             rate (eGFR) ≥ 90 milliliter per minute (mL/min).&#xD;
&#xD;
          -  Body mass index (BMI) ≥ 19.0 and ≤ 40.0 kilograms per meter squared (kg/m²)&#xD;
&#xD;
          -  Male participants who agree to use contraception and female participants of child&#xD;
             bearing potential must agree to use contraceptive methods and women not of child&#xD;
             bearing potential can participate.&#xD;
&#xD;
        Participants with Renal Impairment:&#xD;
&#xD;
          -  Have acceptable blood pressure (BP) and pulse rate, as determined by the investigator&#xD;
&#xD;
          -  Participants with type 2 diabetes must have a glycated hemoglobin (HbA1c) ≥ 5.0% and ≤&#xD;
             11.5%&#xD;
&#xD;
          -  Are males or females with severe renal impairment as determined by a stable eGFR &lt;30&#xD;
             mL/min, not requiring hemodialysis OR&#xD;
&#xD;
          -  Are males or females with end-stage renal disease (have received hemodialysis for at&#xD;
             least 3 months)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have known allergies to LY3437943 or related compounds&#xD;
&#xD;
          -  Have a current, functioning organ transplant. Nonfunctional renal allografts may be&#xD;
             allowed&#xD;
&#xD;
          -  Have any abnormality in the 12-lead electrocardiogram (ECG)&#xD;
&#xD;
          -  Are women with a positive pregnancy test or women who are lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@Lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>7145509990</phone>
    </contact>
    <investigator>
      <last_name>JOEL MICHAEL NEUTEL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>305-817-2900</phone>
    </contact>
    <investigator>
      <last_name>Alexander Prezioso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>407-240-7878</phone>
    </contact>
    <investigator>
      <last_name>Thomas C Marbury</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nucleus Networks</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>612-315-6490</phone>
    </contact>
    <investigator>
      <last_name>Trisha Shamp</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 1, 2023</verification_date>
  <study_first_submitted>November 3, 2022</study_first_submitted>
  <study_first_submitted_qc>November 3, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2022</study_first_posted>
  <last_update_submitted>April 12, 2023</last_update_submitted>
  <last_update_submitted_qc>April 12, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

